首頁 > 市場調查報告書 > 製藥

疼痛

市場調查報告書

商品編碼

1900030

疼痛管理治療市場規模、佔有率和成長分析（按藥物類別、適應症、通路和地區分類）－2026-2033年產業預測

Pain Management Therapeutics Market Size, Share, and Growth Analysis, By Drug Class (NSAIDs, Anesthetics), By Indication (Arthritic Pain, Neuropathic Pain), By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 276 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球疼痛管理藥物市場規模預計在 2024 年達到 815.3 億美元，從 2025 年的 844.7 億美元成長到 2033 年的 1120.9 億美元，在預測期（2026-2033 年）內複合年成長率為 3.6%。

疼痛管理治療市場正日益採用多管齊下的方法來有效治療急性和慢性疼痛。雖然醫生通常會將疼痛管理納入醫療程序，但複雜的病例往往需要專門的疼痛管理干預措施。這個專業領域涵蓋多種疾病，包括纖維肌痛、神經病變疼痛、慢性下背痛、關節炎、術後疼痛、癌症疼痛和偏頭痛。然而，由於政府和製藥公司削減資金，導致疼痛倡導組織的影響力和資金籌措減少，市場成長面臨挑戰。這些組織在提高公眾意識和推廣治療方案方面發揮著至關重要的作用，因此其影響力的下降可能會阻礙疼痛管理治療的整體進展，並影響這一重要醫療保健領域未來的發展機會。

全球疼痛管理治療市場促進因素

全球疼痛管理治療市場的擴張受到多種疾病日益普遍的顯著影響，這些疾病會導致各種形式的疼痛和不適。潰瘍、骨關節炎、慢性關節炎、多發性硬化症、癌症和糖尿病神經病變等疾病都是常見的疼痛原因，需要有效的治療方案。疼痛管理療法能夠有效應對從急性發作到慢性疼痛等各種類型的疼痛，從而推動了市場需求。此外，人們越來越傾向於採取積極主動的疼痛管理策略，這進一步促進了這一重要醫療保健領域的成長，凸顯了這些療法在改善患者生活品質方面發揮的關鍵作用。

限制全球疼痛管理治療市場發展的因素

阻礙全球疼痛管理治療市場成長的關鍵因素之一是人們對處方藥物濫用問題的日益關注。這些藥物通常並非依照醫護人員的指導服用，其濫用會帶來嚴重的健康風險，而這些風險往往被低估。此類濫用可能導致嚴重的健康併發症，在極端情況下甚至可能致命。大眾對這些危險的認知不斷提高，可能會促使對處方箋止痛藥進行更嚴格的審查和監管，從而影響市場動態，並促使患者尋求其他疼痛管理方案。

全球疼痛管理藥物市場趨勢

全球疼痛管理治療市場正經歷顯著的轉變，個人化醫療、生物製藥和快速起效的生活方式療法正成為主流，目前這些療法在研發領域佔據主導地位，佔新治療方法總數的70%以上。這一轉變反映出人們對疼痛管理複雜性的認知不斷加深，醫療服務提供者正在尋求能夠提高療效並最大限度減少副作用的個人化治療方案。此外，生物技術和基因組學的進步也促進了標靶治療的開發，使其更貼近患者的個別需求。隨著對創新有效止痛方案的需求不斷成長，預計市場將在治療方法模式上進一步發展，更加貼近以患者為中心的護理模式。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

CSL Behring（Australia）
Takeda Pharmaceutical Company Limited（Japan）
Pharming Group NV（Netherlands）
BioCryst Pharmaceuticals, Inc.（USA）
Ionis Pharmaceuticals, Inc.（USA）
Sanofi SA（France）
Adverum Biotechnologies, Inc.（USA）
KalVista Pharmaceuticals, Inc.（USA）
Attune Pharmaceuticals, Inc.（USA）
Arrowhead Pharmaceuticals, Inc.（USA）
Amgen Inc.（USA）
BioMarin Pharmaceutical Inc.（USA）
Catalyst Biosciences, Inc.（USA）
RUCONEST（Pharming Group NV, Netherlands）
Haegarda（CSL Limited, Australia）
Firazyr（Shire plc, UK）
Shire plc（UK）
Dyax Corp.（USA）
Adverum Biotechnologies, Inc.（USA）
Amgen Inc.（USA）

結論與建議

簡介目錄

Product Code: SQMIG35F2004

Global Pain Management Therapeutics Market size was valued at USD 81.53 Billion in 2024 and is poised to grow from USD 84.47 Billion in 2025 to USD 112.09 Billion by 2033, growing at a CAGR of 3.6% during the forecast period (2026-2033).

The pain management therapeutics market reveals a growing trend toward employing a multidisciplinary approach to treat both acute and chronic pain effectively. Physicians routinely integrate pain control into medical procedures but often require specialized pain management interventions for complex cases. This specialty addresses various conditions, including fibromyalgia, neuropathic pain, chronic back pain, arthritis, post-operative pain, cancer pain, and migraines. However, the market growth faces challenges due to the declining influence and funding of pain advocacy organizations, stemming from cuts from both government and pharmaceutical sponsors. As these organizations play a crucial role in promoting awareness and advancing treatment options, their diminished power may hinder the overall progress in pain management therapies, affecting future opportunities in this essential healthcare segment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pain Management Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pain Management Therapeutics Market Segments Analysis

Global Pain Management Therapeutics Market is segmented by Drug Class, Indication, Distribution channel and region. Based on Drug Class, the market is segmented into NSAIDs, Anesthetics, Anticonvulsants, Anti-migraine Agents, Antidepressants, Opioids, Nonnarcotic Analgesics and Others. Based on Indication, the market is segmented into Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, Fibromyalgia, Muscle Sprain/Strain, Bone Fracture, Acute Appendicitis and Others. Based on Distribution channel, the market is segmented into Online Pharmacy, Hospital Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pain Management Therapeutics Market

The expansion of the global pain management therapeutics market is significantly influenced by the rising prevalence of multiple diseases, which bring about various forms of pain and discomfort. Conditions such as ulcers, osteoarthritis, chronic arthritis, multiple sclerosis, cancer, and diabetic neuropathy are common sources of pain that necessitate effective management solutions. The effectiveness of pain management therapies in addressing a wide range of pain types, from acute episodes to chronic conditions, is driving demand. Additionally, an increasing preference for proactive pain management strategies is further propelling the growth of this vital healthcare sector, highlighting the essential role these therapeutics play in improving quality of life.

Restraints in the Global Pain Management Therapeutics Market

One significant factor that may hinder the growth of the Global Pain Management Therapeutics market is the rising concern surrounding prescription drug abuse. The misuse of these medications, often taken in ways not directed by healthcare professionals, poses considerable health risks that are frequently underestimated. Such abuse can lead to severe health complications and, in extreme cases, even result in fatal outcomes. As public awareness of these dangers increases, it may foster greater scrutiny and regulation surrounding prescription pain medications, which in turn could impact the market dynamics and drive patients towards alternative pain management solutions.

Market Trends of the Global Pain Management Therapeutics Market

The Global Pain Management Therapeutics market is experiencing a significant trend towards personalized medicine, biologics, and rapid-acting lifestyle therapies, which now dominate the developmental landscape, constituting over 70% of new treatments. This shift reflects a growing recognition of the complexity of pain management, as healthcare providers seek tailored approaches that enhance efficacy and minimize side effects. Moreover, advancements in biotechnology and genomics are facilitating the creation of targeted therapies that align more closely with patient-specific needs. As the demand for innovative and effective pain relief solutions rises, the market is likely to see further evolution in its therapeutic offerings, aligning closely with patient-centric care models.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technology Analysis
Patent Analysis

Global Pain Management Therapeutics Market Size by Drug Class & CAGR (2026-2033)

Market Overview
NSAIDs
Anesthetics
Anticonvulsants
Anti-migraine Agents
Antidepressants
Opioids
Nonnarcotic Analgesics
Others

Global Pain Management Therapeutics Market Size by Indication & CAGR (2026-2033)

Market Overview
Arthritic Pain
Neuropathic Pain
Cancer Pain
Chronic Back Pain
Postoperative Pain
Migraine
Fibromyalgia
Muscle Sprain/Strain
Bone Fracture
Acute Appendicitis
Others

Global Pain Management Therapeutics Market Size by Distribution channel & CAGR (2026-2033)

Market Overview
Online Pharmacy
Hospital Pharmacy
Retail Pharmacy

Global Pain Management Therapeutics Market Size & CAGR (2026-2033)

North America (Drug Class, Indication, Distribution channel)
- US
- Canada
Europe (Drug Class, Indication, Distribution channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Indication, Distribution channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Indication, Distribution channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Indication, Distribution channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

CSL Behring (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pharming Group N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioCryst Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ionis Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adverum Biotechnologies, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KalVista Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Attune Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Arrowhead Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioMarin Pharmaceutical Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalyst Biosciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RUCONEST (Pharming Group N.V., Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Haegarda (CSL Limited, Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Firazyr (Shire plc, UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shire plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dyax Corp. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adverum Biotechnologies, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments